2026-01-02 - Analysis Report
Okay, here's a comprehensive analysis of Hims & Hers Health Inc. (HIMS) based on the provided data.

**0) Data Overview**

*   **Ticker:** HIMS
*   **Company Name:** Hims & Hers Health Inc.

**1) Return Rate Comparison**

*   **Company Overview:** Hims & Hers Health Inc. is a telehealth company that offers personalized health and wellness solutions.
*   **HIMS Cumulative Return:** 109.66%
*   **VOO (S&P 500) Cumulative Return:** 75.26%
*   **Divergence:** 34.4 (Relative Divergence: 29.6)

**Analysis:** HIMS has significantly outperformed the S&P 500 over the tracked period, with a cumulative return exceeding the market benchmark by approximately 34.4%. The relative divergence of 29.6 suggests that the current performance is positioned within the lower end of its historical fluctuation range relative to the S&P 500.

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD   | Alpha   | Beta | Cap(B) |
|------------|---------|-------|---------|------|--------|
| 2020-2022  | -36.0%  | 86.1% | -55.0%  | 0.7  | 1.5    |
| 2021-2023  | -53.0%  | 86.1% | -82.0%  | 1.6  | 2.0    |
| 2022-2024  | 395.0%  | 79.6% | 365.0%  | 1.7  | 5.5    |
| 2023-2025  | 292.0%  | 80.8% | 224.0%  | 2.1  | 7.4    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate shows a volatile trend. The initial periods (2020-2022 and 2021-2023) show significant negative growth, while the later periods (2022-2024 and 2023-2025) exhibit substantial positive growth. This indicates a potential turnaround or a shift in market sentiment towards the company.
*   **MDD:** The Maximum Drawdown is consistently high, around 80-86%, highlighting the significant risk associated with the stock.
*   **Alpha:** Alpha consistently increases, starting with negative values (-55.0%, -82.0%) and shifting to strongly positive values (365.0%, 224.0%). This demonstrates that the stock has started to generate excess returns compared to its benchmark, particularly in recent periods.
*   **Beta:** Beta is consistently above 1, indicating that HIMS is more volatile than the market. The increasing Beta (0.7, 1.6, 1.7, 2.1) suggests that the stock's sensitivity to market movements has increased over time.
*   **Cap(B):** The Market Capitalization has increased substantially over the periods, reflecting the growth of the company.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** $32.47
*   **Previous Close:** $33.04
*   **Change:** -1.73%
*   **5-day SMA:** $33.72
*   **20-day SMA:** $36.25
*   **60-day SMA:** $42.00

**Analysis:** The stock price is currently trending downwards as it is below all its Simple Moving Averages (SMA). The 5-day SMA is below the 20-day SMA, which in turn is below the 60-day SMA, confirming this downward trend. The negative change from the previous close suggests continued downward pressure.

**3) Indicator Analysis**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 17.05 (Oversold)
*   **PPO:** -0.46
*   **Hybrid Signal:** cash\_0% Buy 100% of cash (26 shares - Very Safe - MRI:0.90) Monthly invest 1.3% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** -3.2 (Short-term decline)
*   **Expected Return (%):** 329.75%

**Analysis:**

*   **MRI:** Despite the high investment recommendation, it's crucial to consider other factors.
*   **RSI:** The RSI indicates the stock is heavily oversold, suggesting a potential for a rebound.
*   **PPO:** The negative PPO value indicates that the short-term moving average is below the long-term moving average, confirming the downward trend.
*   **Hybrid Signal:** The signal suggests a strong buy recommendation, driven by the MRI.
*   **Delta\_Previous\_Relative\_Divergence:** The negative change indicates a short-term decline, which aligns with the recent price fluctuations.
*   **Expected Return:** The high expected return suggests that the model predicts significant potential upside from the current price level, especially for long-term investors.

**4) Recent News & Significant Events**

*   **[2025-12-16]** "Hims & Hers Health (HIMS): Taking Stock of Valuation After a Sharp 90‑Day Pullback" - This suggests concerns about valuation following a price decrease.
*   **[2026-01-01]** "HIMS Stock Falls -8.7% With A 7-day Losing Spree On Valuation Concerns" - Reinforces concerns about valuation and recent negative price action.
*   **[2025-11-17]** "Hims & Hers Health, Inc. Announces $250 Million Share Repurchase Program Authorization" - A share repurchase program can boost investor confidence by indicating the company believes its stock is undervalued.
*   **[2025-12-29]** "Hims & Hers stock slides into year-end as investors weigh Ohio buildout and macro calendar" - Indicates that investors are considering the company's expansion plans and broader economic factors.
*   **[2025-12-13]** "$HIMS stock fell 6% this week. Here's what we see in our data." - Another indicator of recent price weakness.
*   **[2025-12-29]** "Why HIMS Stock Is Up 36% In 2025" - Provides a contrasting perspective, highlighting the stock's overall positive performance for the year.

**Analysis:** The news headlines present a mixed picture. There are recurring concerns about valuation leading to recent price declines. However, the share repurchase program suggests the company believes its stock is undervalued. The Ohio buildout and macro calendar mentions highlight that investors are also considering broader factors that could impact the company's future performance. The article noting the 36% gain in 2025 places the recent downturn in the context of a generally positive year.

**4-2) Analyst Opinions**

*   **Mean Analyst Recommendation:** None provided
*   **Number of Opinions:** 12
*   **Average Target Price:** $44.67
*   **High Target Price:** $85.00
*   **Low Target Price:** $25.00
*   **Recent Rating Changes:** No changes provided

**Analysis:** The average target price of $44.67 suggests analysts, on average, believe the stock has significant upside potential from its current price of $32.47. However, the wide range between the high and low target prices indicates a divergence in opinions about the stock's future performance.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출     |
|------------|------|----------|
| 2025-11-03 | 0.07 | 0.60 B$  |
| 2025-08-04 | 0.19 | 0.54 B$  |
| 2025-05-05 | 0.22 | 0.59 B$  |
| 2024-11-04 | 0.35 | 0.40 B$  |
| 2025-11-03 | 0.35 | 0.40 B$  |

**Analysis:**

*   **EPS:** Earnings Per Share (EPS) is volatile across the quarters. There seems to be an unusual duplication of the EPS and Revenue in the last two rows, which suggests there may be incorrect data.
*   **Revenue:** Revenue generally shows an upward trend, indicating that the company's sales are increasing.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $0.60B    | 73.80%        |
| 2025-06-30   | $0.54B    | 76.39%        |
| 2025-03-31   | $0.59B    | 73.50%        |
| 2024-12-31   | $0.48B    | 76.81%        |
| 2024-09-30   | $0.40B    | 79.16%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE     |
|--------------|-----------|---------|
| 2025-09-30   | $0.58B    | 2.72%   |
| 2025-06-30   | $0.56B    | 7.55%   |
| 2025-03-31   | $0.55B    | 9.01%   |
| 2024-12-31   | $0.48B    | 5.46%   |
| 2024-09-30   | $0.44B    | 17.18%  |

**Analysis:**

*   **Revenue and Profitability:**
    *   Revenue has been increasing steadily over the past five quarters, indicating strong sales growth.
    *   Profit Margins remain high, consistently above 70%, suggesting the company has good cost control and pricing power.
*   **Capital and Profitability:**
    *   Equity has been increasing, which is generally a positive sign as it indicates that the company's net worth is growing.
    *   Return on Equity (ROE) has fluctuated. It was high in Q3 2024 but has generally decreased over the subsequent quarters, which could be a concern if the trend continues.

**7) Comprehensive Analysis (Summary)**

Hims & Hers Health Inc. (HIMS) presents a mixed investment picture.

*   **Positives:**
    *   Outperformed the S&P 500 significantly.
    *   High expected return.
    *   Strong revenue growth and high profit margins.
    *   Analyst target prices suggest upside potential.
    *   Share repurchase program indicates confidence in the stock's value.
*   **Negatives:**
    *   Recent price decline and negative short-term trends.
    *   Concerns about valuation.
    *   High volatility (Beta).
    *   Declining ROE in recent quarters.
    *   The MRI is high, indicating it is a good time to invest, but the RSI is low, indicating it is oversold.

**Conclusion:**

HIMS appears to be a high-growth company with strong revenue and profitability metrics. However, the stock is volatile and has experienced recent price weakness due to valuation concerns. The high expected return and analyst target prices suggest potential upside, but investors should be aware of the risks associated with the stock's volatility and recent downward trend. The oversold RSI coupled with a high MRI provides conflicting signals. It is recommended to do more fundamental analysis and watch out for upcoming financial releases to confirm positive insights and potentially change in short-term trends.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.